FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
Daily1d
USFDA accepts for review application for GSK Blenrep combinations for multiple myeloma treatment
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Pharmabiz1d
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
The Pharma Letter1d
FDA signals progress on the western front for belantamab mafodotin
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...
GSK eyes up combo approval for previously withdrawn myeloma drug
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
GSK’s Blenrep Nears FDA Review for Myeloma
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
GSK's Blenrep treatment accepted for review by FDA
Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...
GSK's Blenrep combinations accepted for review by US FDA
GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory multiple myeloma, both ...
GSK :FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory Multiple Myeloma
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
businesslive.co.za4d
Why the Competition Commission’s decision on two cancer drug cases could have wider implications
There is a history of competition law being used to drive HIV medicine prices lower in South Africa. Now, two cases involving ...
The American Journal of Managed Care5d
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
News246d
Why the Competition Commission's decision on cancer medicine cases could have much wider implications
The Competition Commission played a pivotal role in South Africa's historic fight for access to HIV medicines.